Tissue Repository Core

摘要-儿科风湿病组织库(PRTR) 强大而严谨的生物样品收集基础设施对于加速创新的翻译是必不可少的 儿科风湿病研究项目。儿科风湿病组织库(PRTR)是 成立于1996年，一直得到NIAMS资金的支持，以实现样本价值的最大化 翻译研究的收藏品。自2017年以来，PRTR一直是美国儿童生物库 关节炎风湿学研究联盟(CARA)研究注册，儿科最大的纵向研究 北美的风湿病。拟议的减贫战略的总体目标是加速变革 通过促进获得有价值的高质量生物检疫药物在儿科风湿病方面的发现 创新的翻译研究项目。为实现这一目标，提出了以下目标。在第一个 目的：PRTR将收集、处理和维护来自儿科患者的高质量生物标本。 风湿病和相关的肌肉骨骼疾病，以支持和发展当地的研究社区。这 包括促进专门针对调查员的大规模样本收集的设计和管理- 发起了翻译研究。这还包括正在收集的高价值生物样品(新发病 疾病和残留液和组织)，并支持由早期调查人员进行试点生物样本收集 他们有创新的研究方向，但缺乏实验室基础设施。在目标2中，革命制度改革方案将扩大 全国儿科风湿病研究生物样品采集范围。Prtr将支持 适用于新兴基因组的先进生物样品的开发和实施 方法，特别是来自非血液组织的方法，包括超声引导的滑膜和肾脏活检，骨 骨髓、支气管肺泡灌洗(BAL)和肺组织。与此同时，冲突后恢复和恢复工作小组与 将利用CARA来支持方案制定、研究设计援助、现场培训和 在各个CARRA登记处开展先进处理的基础设施建设。最后，在目标3中， PRTR将优化生物样本收集的可获得性、获取和使用。这包括近实时、等分- 已验证的、完全集成的表型和生物库信息的级别、未识别的标本数据 将继续通过RheumsMart进行搜索，RheumsMart是PRTR的安全在线数据集市。我们还将升级 将本地和CARA收藏品的生物库跟踪系统连接到行业领先的LabVantage LIMS。已被占用 总而言之，PRTR将为生物标本收集提供一个集中的、高质量的、有价值的资源， 加工和存储，以支持CCHMC和全国的研究社区。这些资源将 加快翻译研究倡议，以推进CRDRC的总体目标 了解儿童风湿性疾病，并导致这些疾病的新疗法。

Abstract – Pediatric Rheumatology Tissue Repository (PRTR) A robust and rigorous infrastructure for biospecimen collection is essential for accelerate innovative translational research projects in pediatric rheumatology. The Pediatric Rheumatology Tissue Repository (PRTR) was established in 1996 and has been continuously supported by NIAMS funding to maximize the value of sample collections for translational research. Since 2017, the PRTR has served as the US biobank for the Childhood Arthritis Rheumatology Research Alliance (CARRA) Research Registry, the largest longitudinal study of pediatric rheumatic diseases in North America. The overall objective of the proposed PRTR is to accelerate transformative discovery in pediatric rheumatology by facilitating access to valuable and high quality biospecimens for innovative translational research projects. The following aims are proposed to achieve this objective. In the first aim, the PRTR will collect, process and maintain high quality biological specimens from patients with pediatric rheumatologic and related musculoskeletal conditions to support and grow the local research community. This includes facilitating the design and management of large-scale sample collections specific to investigator- initiated translational research. This also includes ongoing collection of high value biospecimens (new-onset disease and leftover fluid and tissue), and support for pilot biosample collections by early-stage investigators with innovative research directions but who lack laboratory infrastructure. In Aim 2, the PRTR will expand the scope of biospecimen collection for pediatric rheumatic disease research nationally. The PRTR will support development and implementation of advanced biospecimen collections suitable for emerging genomic approaches, particularly from non-blood tissues including ultrasound-guided synovial and kidney biopsy, bone marrow, bronchoalveolar lavage (BAL), and lung tissue. In parallel, the partnership between the PRTR and CARRA will be leveraged to support protocol development, study design assistance, site training, and infrastructure development for advanced processing at individual CARRA Registry sites. Finally in Aim 3, the PRTR will optimize availability, access to and use of biosample collections. This includes near-real-time, aliquot- level, de-identified specimen data to authenticated, and fully integrated phenotypic and biobanking information will continue to be searchable through RheumsMart, the PRTR’s secure online data mart. We will also upgrade biobanking tracking system for both local and CARRA collections to industry-leading LabVantage LIMS. Taken together, the PRTR will provide a centralized, high quality, valuable resource for biospecimen collection, processing, and storage to support the Research Community at CCHMC and nationally. These resources will accelerate translational research initiatives to further the overall goal of the CRDRC to advance the understanding of pediatric rheumatic diseases and lead to new therapies for these diseases.